Medical Technology Analyst Newitter and Biotech Analyst Germino, along with Dr. Gartrell, Director of Genitourinary Oncology, Dr. Laccetti, Asst Genitourinary Medical Oncology at Memorial Sloan Kettering Cancer Center, discuss Lantheus/POINT Biopharma PSMA radioligands and provide views on SPLASH and PSMAfore on an Analyst/Industry conference call to be held on September 26 at 11 am. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LNTH:
- Truist med tech/biotech analysts hold analyst/industry conference call
- Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting
- Lantheus announces agreement to sell RELISTOR royalties to HealthCare Royalty
- Lantheus Announces Agreement to Sell RELISTOR® Royalties to HealthCare Royalty
- Lantheus adjusts FY23 adjusted EPS view to $5.60-$5.70 from $5.45-$5.70
